18910-70-8

Basic information

• Product Name: Levalbuterol Related Compound C (30 mg) (alpha-[{(1,1-Dimethylethyl)amino}methyl]-4-hydroxy-3-(methoxymethyl)-benzenemethanol)
• Synonyms: (R)-4-(2-(tert-butylamino)-1-hydroxyethyl)-2-(methoxymethyl)phenol;Levalbuterol Related Compound C (30 mg) (alpha-[{(1,1-Dimethylethyl)amino}methyl]-4-hydroxy-3-(methoxymethyl)-benzenemethanol);O-Methyl Albuterol;Levalbuterol Related CoMpound C;Salbutamol Impurity M;4-(2-(tert-butylamino)-1-hydroxyethyl)-2-(methoxymethyl)phenol;Salbutamol EP Impurity M
• CAS NO: 18910-70-8
• Molecular Formula: C₁₄H₂₃NO₃
• Molecular Weight: 253.33732
• Mol File: 18910-70-8.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 402.2±40.0 °C(Predicted)
• Appearance: /
• Density: 1.087±0.06 g/cm3(Predicted)
• PKA: 9.53±0.50(Predicted)
• CAS DataBase Reference: Levalbuterol Related Compound C (30 mg) (alpha-[{(1,1-Dimethylethyl)amino}methyl]-4-hydroxy-3-(methoxymethyl)-benzenemethanol)(CAS DataBase Reference)
• NIST Chemistry Reference: Levalbuterol Related Compound C (30 mg) (alpha-[{(1,1-Dimethylethyl)amino}methyl]-4-hydroxy-3-(methoxymethyl)-benzenemethanol)(18910-70-8)
• EPA Substance Registry System: Levalbuterol Related Compound C (30 mg) (alpha-[{(1,1-Dimethylethyl)amino}methyl]-4-hydroxy-3-(methoxymethyl)-benzenemethanol)(18910-70-8)

Safety Data

• Hazardous Substances Data: 18910-70-8(Hazardous Substances Data)

Usage

Uses

O-Methyl Albuterol (Levalbuterol USP Related Compound C) is an impurity in the synthesis of Albuterol (A514501), rac Albuterol is a β2-adrenoceptor agonist. Bronchodilator; tocolytic.

Upstream product

• 67-56-1 methanol 
• 348135-26-2 (R)-α1-[[(1,1-dimethylethyl)amino]methyl]-4-hydroxy-1,3-benzenedimethanol D-dibenzoyltartrate 

Relevant articles and documents

Preparation of levalbuterol hydrochloride

Provided are processes for the preparation of (R)-SLB.D-DBTA salt and levalbuterol hydrochloride. Also provided are levalbuterol hydrochloride degradation products and processes for preparing them. Pharmaceutical compositions comprising at least one levalbuterol hydrochloride of the invention and at least one pharmaceutically-acceptable excipient are also provided.